Report cover image

Cancer Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Publisher IMARC Services Pvt. Ltd.
Published Feb 03, 2023
Length 145 Pages
SKU # IMRC17761329

Description

Cancer Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Overview:

The global cancer diagnostics market size reached US$ 186.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 266.4 Billion by 2028, exhibiting a growth rate (CAGR) of 5.9% during 2023-2028.

Cancer diagnostics represent a range of assessments and procedures executed using sophisticated technologies to identify biomarkers, proteins, tumor type, location, and signs about the stage and presence of various cancerous tumors. They encompass imaging, tumor biopsy, laboratory tests, immunohistochemistry genetic testing, and endoscopic examination as standard assessments. These diagnostics methodologies are performed based on the patient condition and severity of disorders. Apart from this, cancer diagnostics help healthcare practitioners in developing a personalized treatment plan, evaluating specific antigens in a sample tissue by using antibodies, and providing better clinical outcomes through early diagnosis and care. As a result, they are widely adopted in hospitals and laboratories to examine breast, lung, melanoma, and colorectal cancer. Currently, they are mainly available in fluorescent in situ and comparative genomic hybridization technologies.

Cancer Diagnostics Market Trends:

The increasing prevalence of cancer, owing to the rising consumption of alcoholic beverages and tobacco-based products, and the growing need for preventive, diagnostic technologies for better therapeutic effects are majorly driving the market growth. In line with this, significant enhancements in the healthcare sector and the advent of advanced oncological imaging modalities and imaging technologies to detect infections with enhanced accuracy are acting as another growth-inducing factor. Additionally, extensive investments by pharmaceutical companies to engineer cancer vaccines and novel biomarkers for the identification of potential tumor is contributing to the market growth. Moreover, the favorable initiatives being undertaken by non-governmental organizations (NGOs) and healthcare practitioners to sensitize individuals regarding the availability and benefits of early cancer diagnosis, such as instant decision-making and consequent treatment, are propelling the market growth. Other factors, such as the rapid establishment of private diagnostic centers and ongoing research and development (R&D) activities to design effective product variants with reduced treatment, hospitalization, and unavoidable intervention costs, are positively augmenting the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer diagnostics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, technology, application and end user.

Breakup by Product:

Consumables
Antibodies
Kits and Reagents
Probes
Others
Instru
Pathology-based Instruments
Imaging Instruments
Biopsy Instruments

Breakup by Technology:

IVD Testing
Polymerase Chain Reaction (PCR)
In Situ Hybridization (ISH)
Immunohistochemistry (IHC)
Next-generation Sequencing (NGS)
Microarrays
Flow Cytometry
Immunoassays
Others
Imaging
Magnetic Resonance Imaging (MRI)
Computed Tomography (CT)
Positron Emission Tomography (PET)
Mammography
Ultrasound
Biopsy Technique

Breakup by Application:

Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Others

Breakup by End User:

Hospitals and Clinics
Diagnostic Laboratories
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG (Roche Holding AG), GE HealthCare (General Electric Company), Hologic Inc., Illumina Inc., Koninklijke Philips N.V., Pfizer Inc., Qiagen N.V, Quest Diagnostics, Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

How has the global cancer diagnostics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global cancer diagnostics market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global cancer diagnostics market and who are the key players?
What is the degree of competition in the industry?

Table of Contents

145 Pages
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Cancer Diagnostics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Consumables
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Antibodies
6.1.2.2 Kits and Reagents
6.1.2.3 Probes
6.1.2.4 Others
6.1.3 Market Forecast
6.2 Instruments
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Pathology-based Instruments
6.2.2.2 Imaging Instruments
6.2.2.3 Biopsy Instruments
6.2.3 Market Forecast
7 Market Breakup by Technology
7.1 IVD Testing
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 Polymerase Chain Reaction (PCR)
7.1.2.2 In Situ Hybridization (ISH)
7.1.2.3 Immunohistochemistry (IHC)
7.1.2.4 Next-generation Sequencing (NGS)
7.1.2.5 Microarrays
7.1.2.6 Flow Cytometry
7.1.2.7 Immunoassays
7.1.2.8 Others
7.1.3 Market Forecast
7.2 Imaging
7.2.1 Market Trends
7.2.2 Key Segments
7.2.2.1 Magnetic Resonance Imaging (MRI)
7.2.2.2 Computed Tomography (CT)
7.2.2.3 Positron Emission Tomography (PET)
7.2.2.4 Mammography
7.2.2.5 Ultrasound
7.2.3 Market Forecast
7.3 Biopsy Technique
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Application
8.1 Breast Cancer
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Lung Cancer
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Colorectal Cancer
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Melanoma
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Others
8.5.1 Market Trends
8.5.2 Market Forecast
9 Market Breakup by End User
9.1 Hospitals and Clinics
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Diagnostic Laboratories
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Abbott Laboratories
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Agilent Technologies Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Becton Dickinson and Company
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Bio-Rad Laboratories Inc.
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 SWOT Analysis
15.3.6 GE HealthCare (General Electric Company)
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.7 Hologic Inc.
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Illumina Inc.
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Koninklijke Philips N.V.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Pfizer Inc.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Qiagen N.V
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 Quest Diagnostics
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.12.4 SWOT Analysis
15.3.13 Siemens Healthineers AG (Siemens AG)
15.3.13.1 Company Overview
15.3.13.2 Product Portfolio
15.3.13.3 Financials
15.3.13.4 SWOT Analysis
15.3.14 Thermo Fisher Scientific Inc.
15.3.14.1 Company Overview
15.3.14.2 Product Portfolio
15.3.14.3 Financials
15.3.14.4 SWOT Analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us